Arrowhead Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 525
- Market Cap
- $2.9B
- Introduction
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Clinical Trials
74
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (71 trials with phase data)• Click on a phase to view related trials
Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia
- Conditions
- Hyperlipidemia; Mixed
- Interventions
- Drug: ARO-DIMERPADrug: Placebo
- First Posted Date
- 2025-11-03
- Last Posted Date
- 2025-11-03
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 78
- Registration Number
- NCT07223658
Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease
- Conditions
- Alzheimer DiseaseAlzheimer Disease, Early Onset
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-10-27
- Last Posted Date
- 2025-10-27
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT07221344
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
- Conditions
- Homozygous Familial Hypercholesterolemia
- Interventions
- Drug: zodasiran InjectionDrug: Placebo
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-10-10
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT07037771
- Locations
- 🇺🇸
Research Site 2, New York, New York, United States
🇺🇸Research Site 1, Cincinnati, Ohio, United States
Study of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-09-17
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 126
- Registration Number
- NCT06937203
- Locations
- 🇳🇿
Research Site, Auckland, New Zealand
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT06880770
- Locations
- 🇺🇸
Clinical Research Site 4, Santa Clarita, California, United States
🇺🇸Clinical Research Site 6, Springfield, Illinois, United States
🇺🇸Clinical Research Site 5, North Platte, Nebraska, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next
News
Advanced Drug Delivery Technologies Drive Biotech Innovation as Nanomedicine Market Approaches $430 Billion
The global nanomedicine market is projected to grow from approximately $245 billion in 2023 to over $430 billion by 2028, driven by increasing adoption in oncology, neurology, and regenerative medicine.
Arrowhead Pharmaceuticals Files Patent Lawsuit Against Ionis Over Plozasiran FCS Treatment
Arrowhead Pharmaceuticals filed a declaratory judgment complaint against Ionis Pharmaceuticals in Delaware federal court, challenging the validity of Ionis's U.S. Patent No. 9,593,333 and asserting non-infringement by plozasiran.
Arrowhead Pharmaceuticals Advances Two Breakthrough RNAi Therapeutics into Clinical Trials
Arrowhead Pharmaceuticals has filed regulatory applications for two innovative RNAi therapeutics: ARO-DIMER-PA for mixed hyperlipidemia and ARO-MAPT for Alzheimer's disease.
Sanofi Acquires Rights to Plozasiran for $395 Million in Greater China Deal with Arrowhead
Sanofi has acquired rights to develop and commercialize plozasiran, a first-in-class RNAi therapeutic for familial chylomicronemia syndrome and severe hypertriglyceridemia, in Greater China for $130 million upfront plus up to $265 million in milestones.
Arrowhead Pharmaceuticals Receives $100 Million Milestone Payment for ARO-DM1 Myotonic Dystrophy Treatment
Arrowhead Pharmaceuticals earned a $100 million milestone payment from Sarepta Therapeutics after reaching enrollment targets for ARO-DM1, an RNAi therapeutic for type 1 myotonic dystrophy.
CNS Oligonucleotide Licensing Deals Surge 339% to $2.81 Billion in 2024
Licensing agreements for CNS-targeted oligonucleotide therapeutics increased 339% from 2023 to 2024, reaching $2.81 billion in total deal value according to GlobalData's analysis.
Arrowhead Pharmaceuticals Launches First-in-Human Trial of ARO-ALK7 for Obesity Treatment
Arrowhead Pharmaceuticals has dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, marking the first investigational RNAi therapeutic to target a gene expressed in adipose tissue for obesity treatment.
Plozasiran Shows Promise in Reducing Cholesterol and Triglycerides in Mixed Hyperlipidemia Patients
Plozasiran, an investigational hepatocyte-targeted APOC3 small interfering RNA developed by Arrowhead Pharmaceuticals, demonstrated significant reductions in triglyceride levels and improved lipid profiles in patients with mixed hyperlipidemia.
RAGE Inhibitor Pipeline Shows Promise for Inflammatory Diseases with 5+ Companies Advancing Novel Therapeutics
A comprehensive pipeline analysis reveals over five companies developing RAGE inhibitors across multiple clinical stages, with promising applications in chronic inflammatory diseases and neurodegenerative disorders.
Arrowhead's Plozasiran for Familial Chylomicronemia Syndrome Fast-Tracked for EU Approval
Arrowhead Pharmaceuticals' plozasiran, a novel treatment for familial chylomicronemia syndrome (FCS), has been filed for review by the European Medicines Agency and is being fast-tracked for potential EU marketing approval.